New hope for GVHD patients after multiple failed treatments

NCT ID NCT03604692

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times

Summary

This study tested a drug called axatilimab in 41 people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant where donor cells attack the body. Participants had already tried at least 2 other treatments. The goal was to find a safe dose and see if the drug could improve symptoms. Results showed some patients had partial or complete improvement.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington, 98109, United States

  • Indiana University Health Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana, 46202, United States

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

  • University of Miami Miller School of Medicine

    Miami, Florida, 33136, United States

  • University of Minnesota Medical Center

    Minneapolis, Minnesota, 55455, United States

  • University of Utah Health Huntsman Cancer Institute

    Salt Lake City, Utah, 84112, United States

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee, 37212-3505, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.